Comparative Pharmacology
Head-to-head clinical analysis: AURYXIA versus RENVELA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AURYXIA versus RENVELA.
AURYXIA vs RENVELA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AURYXIA (ferric citrate) is a phosphate binder that reduces serum phosphate by binding dietary phosphate in the gastrointestinal tract, forming insoluble ferric phosphate complexes that are excreted in the feces. The iron component also increases serum iron parameters and may improve iron stores.
Renvela (sevelamer carbonate) is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, inhibiting phosphate absorption and reducing serum phosphate levels. It also binds bile acids, leading to decreased LDL cholesterol.
Adult: 1 tablet (1700 mg ferric citrate) three times daily with meals, titrated every 2-4 weeks to achieve target serum phosphate levels. Maximum dose: 12 tablets per day.
Adults: 800 mg orally three times daily with meals; titrate based on serum phosphorus levels up to 2400 mg per meal (7200 mg/day maximum).
None Documented
None Documented
Not applicable; systemic absorption is minimal. AURYXIA is not absorbed and acts locally in the GI tract.
Not applicable as sevelamer is not absorbed. No systemic half-life; local gastrointestinal transit time is approximately 3-4 hours.
Primarily fecal as unabsorbed drug (≥99%). Renal excretion is negligible (<1%).
Sevelamer carbonate is not absorbed systemically; excretion is entirely fecal as the parent compound. Less than 0.01% is absorbed and excreted renally.
Category C
Category C
Phosphate Binder
Phosphate Binder